文献速递神经肿瘤

近期使用激素避孕药与需手术干预的颅内脑膜瘤风险

Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users.
PubMed 文献 · J Neurooncol · 2026-01-07

该病例对照研究基于Merative Marketscan数据库,纳入15–42岁女性,评估孕激素避孕暴露与需手术治疗的颅内脑膜瘤(STIM)风险的关系。在11,815,164名女性中识别1,218例STIM病例和12,172名对照,发现复方口服避孕药(COC)和肌注/皮下孕激素(IMSC)均增加STIM风险,且IMSC风险高于COC。

要点

  • 近期使用COC与STIM风险升高相关(RR 1.27;95% CI 1.10–1.50)。
  • 近期使用IMSC与STIM风险显著升高相关(RR 3.79;95% CI 2.67–5.40)。
  • 与COC使用者相比,IMSC使用者STIM风险更高(RR 2.98;95% CI 2.06–4.32)。

核心结论

  • 近期使用IMSC与需手术治疗的颅内脑膜瘤风险升高相关,且风险高于无近期激素避孕暴露或COC使用。

研究设计与样本

  • 基于Merative Marketscan研究数据库的病例对照研究,纳入15–42岁、连续入组至少2.5年的女性。
  • STIM病例基于颅内脑膜瘤诊断后接受颅脑脑膜瘤手术操作编码识别,对照按年龄、队列进入日期和随访时间以最多1:10匹配。
  • 激素避孕暴露分为COC、POP、孕激素宫内节育器(IUD)或IMSC,采用多因素条件logistic回归调整合并症估计比值比。

主要发现

  • 在11,815,164名女性中识别1,218例STIM病例和12,172名对照。
  • 与无近期激素避孕使用相比,COC暴露增加STIM风险(RR 1.27;95% CI 1.10–1.50)。
  • 与无近期激素避孕使用相比,IMSC使用增加STIM风险(RR 3.79;95% CI 2.67–5.40)。
  • 与COC使用者相比,IMSC使用者STIM风险更高(RR 2.98;95% CI 2.06–4.32)。

临床怎么用

  • 对需手术治疗的颅内脑膜瘤女性患者,应询问近期激素避孕使用情况,尤其是IMSC类孕激素避孕。
  • 考虑处方针剂型孕激素避孕时,需权衡脑膜瘤手术风险,尤其对有脑膜瘤病史或相关症状者。

局限性

  • 作者指出需进一步研究确认发现,并阐明剂量、使用时长和孕激素制剂差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Progesterones have been implicated in meningioma growth. Long-acting progestin-only hormonal contraceptives (HC) are increasingly popular due to sustained serum progestin levels. This study examined the relationship between progestin-only HC exposure and risk of surgically treated intracranial meningioma (STIM). METHODS: Using the Merative Marketscan research database, we identified females aged 15–42 with at least 2.5 years of continuous enrollment. Within a case-control study, STIM cases were identified based on intracranial meningioma diagnosis followed by cranial meningioma surgery procedure codes. Controls were matched up to 1:10 by age, cohort entry date, and follow-up time. HC exposure was categorized into combined oral estrogen-progestin contraceptives (COC), progestin-only pills (POP), progestin intrauterine device (IUD), or intramuscular/subcutaneous progestin (IMSC). Multivariate conditional logistic regression estimated odds ratios adjusting for comorbidities. RESULTS: Among 11,815,164 women, we identified 1,218 STIM cases and 12,172 controls. Exposure to COC increased STIM risk (RR 1.27; 95% CI 1.10–1.50), as did IMSC use (RR 3.79; 95% CI 2.67–5.40) compared to no recent HC use. Compared to COC users, IMSC users had higher risk (RR 2.98; 95% CI 2.06–4.32). CONCLUSION: IMSC use is associated with increased STIM risk relative to no recent HC exposure or COC use. Further research is needed to confirm our findings and to clarify dose, duration, and progestin agent differences.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Chen S, Jugl S, Jackson L, et al. Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users. J Neurooncol. 2026. PMID: 41498984. doi:10.1007/s11060-025-05402-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。